Olin was founded in 1892 and has been publicly listed since 1917... Show more
Olin Corporation is a leading producer of chemicals and ammunition, operating through its Chlor Alkali Products and Vinyls, Epoxy, and Winchester segments. This quarter carries extra weight because Olin has been navigating a difficult commodity chemicals environment marked by weak prices, subsidized Asian exports, and rising feedstock costs, all of which have squeezed margins. The results also land against the backdrop of the company's proposed merger with Huntsman, a transformational deal that is reshaping investor attention around integration risk and financing. With the stock trading well below its 52-week high and down sharply over the past year, this report was closely watched as a test of whether Olin's "value-first" strategy could stabilize earnings and whether the pending transaction remains on track.
For the third quarter ended September 30, 2026, Olin reported sales of $1.75 billion, up modestly from $1.71 billion in the year-ago period. Net income attributable to Olin Corporation was $14.4 million, or $0.13 per diluted share, compared with $42.8 million in the prior-year quarter. On a GAAP (Generally Accepted Accounting Principles) basis, results came in below the analyst consensus of roughly $0.15–$0.16 per share, while revenue of $1.75 billion missed estimates near $1.83–$1.84 billion.
Adjusted EBITDA was $191.4 million for the quarter, which management described as consistent with its internal expectations. By segment, Chlor Alkali Products and Vinyls sales declined to $850.8 million from $924.0 million a year earlier. Epoxy sales rose to $412.2 million from $349.6 million, and Winchester sales increased to $484.7 million from $439.6 million. Third-quarter acquisition-related costs tied to the pending Huntsman merger totaled $13.7 million.
Looking ahead, Olin guided fourth quarter 2026 adjusted EBITDA to a range of $80 million to $100 million, reflecting normal seasonality, elevated year-end customer destocking in chemicals, higher feedstock costs, and significant planned maintenance turnarounds. The company also indicated it expects the Huntsman transaction to close in the first quarter of 2027, subject to customary closing conditions.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical complement to earnings-focused research. Investors tracking chemical names like Olin can use it to identify similarly positioned opportunities or confirm technical setups before acting.
Heading into the report, sentiment around Olin was cautious. Analyst estimates had drifted lower in the weeks before the release, and the stock had already shed roughly 20% since the start of the year while the broader market advanced. The earnings miss on both the top and bottom lines reinforced existing concerns about commodity chemical pricing and margin compression, even as management emphasized that adjusted EBITDA arrived in line with its own planning. The shares' prior decline from a 52-week high near $30 to levels closer to the mid-teens illustrates the difficult environment the company has faced, and investors have been weighing whether the pending Huntsman combination can eventually create value despite near-term cost and integration uncertainty.
The most immediate signal is Olin's fourth quarter guidance, which points to a sequential step down in adjusted EBITDA to $80 million–$100 million. Management attributed this to normal seasonality, elevated year-end customer destocking in chemicals, higher feedstock costs, continued pressure from subsidized Asian exports, and planned maintenance turnarounds. Investors should watch whether realized chemical prices stabilize or deteriorate further and whether volume recovery can offset pricing weakness.
A second key focus is the Huntsman merger. Olin now expects the transaction to close in the first quarter of 2027, subject to regulatory approvals and other customary conditions. Updates on remaining approvals, integration planning, and financing will be important catalysts, as will the trajectory of acquisition-related costs.
Finally, the company's "Beyond250" structural cost-savings program and its value-first commercial approach remain central to the margin story. Balance sheet metrics also bear watching: Olin ended the quarter with net debt of approximately $2.8 billion and a net debt to adjusted EBITDA ratio of about 5.2 times, underscoring the importance of cash generation and cost discipline in the quarters ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a company which engages in manufacturing and distributing the chemicals products
Industry ChemicalsMajorDiversified